Multiple sclerosis Press Release

Title Picture
09/21/2018 - 00:35
Novartis receives positive CHMP opinion for Gilenya for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
Novartis's picture
Novartis
09/20/2018 - 01:30
New test detects tell-tale danger signs in spinal fluid
YaleUniversity's picture
YaleUniversity
09/12/2018 - 16:26
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya in children and adolescents with MS
Novartis's picture
Novartis
09/12/2018 - 01:53
Major trial of statins to treat multiple sclerosis begins
UniversityCollegeLondon's picture
UniversityColle...
08/30/2018 - 14:09
Study finds multiple sclerosis drug slows brain shrinkage
NIH's picture
NIH
08/29/2018 - 14:11
Phase 2 Clinical Trial of Oral Ibudilast Demonstrates Slowing of Brain Atrophy in Progressive MS
National MS Society's picture
National MS Society
07/30/2018 - 07:56
Thank You Challenge Walk MS National Sponsor
National MS Society's picture
National MS Society
07/16/2018 - 19:06
Genetic marker paves way to prevent serious side effect of multiple sclerosis treatment
BYU's picture
BYU
06/19/2018 - 19:51
Scientists unravel DNA code behind rare neurologic disease
UTSouthwestern's picture
UTSouthwestern
06/14/2018 - 11:08
Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis
Rocheusa's picture
Rocheusa
06/13/2018 - 11:06
Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS
Genentech's picture
Genentech
06/05/2018 - 01:25
UT Southwestern experts help paralyzed college student walk again
UTSouthwestern's picture
UTSouthwestern
05/30/2018 - 02:50
MS Progression Linked to Grey Matter Atrophy
Celgene's picture
Celgene
05/29/2018 - 08:54
Remington College Partners with National Multiple Sclerosis Society for Nationwide Volunteer Effort
wwellons's picture
wwellons
05/11/2018 - 14:28
FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
FDA's picture
FDA
05/09/2018 - 20:34
Spinal Fluid Could be Used to Predict the Progression of Multiple Sclerosis, Study Finds
University of Birmingham's picture
University of B...
04/26/2018 - 18:40
Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE (glatiramer acetate injection) 40 mg/mL
Teva Pharmaceutical's picture
Teva Pharmaceutical
04/24/2018 - 07:33
New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting
Celgene's picture
Celgene
04/23/2018 - 18:04
Guidelines Released by AAN to Help Inform Treatment Choices for Multiple Sclerosis
National MS Society's picture
National MS Society
04/23/2018 - 08:17
Relapsing MS Patients Who Switched to Aubagio (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies
Genzyme's picture
Genzyme
04/23/2018 - 06:24
Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada (alemtuzumab) in Clinical Trials
Genzyme's picture
Genzyme
04/21/2018 - 21:37
New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis
Genentech's picture
Genentech
04/16/2018 - 02:52
Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
Rocheusa's picture
Rocheusa
04/15/2018 - 00:14
Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
Genentech's picture
Genentech
04/10/2018 - 05:39
Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
Mylan's picture
Mylan
04/04/2018 - 03:19
NICE says initial 'no' to ocrelizumab for relapsing MS
MS Society's picture
MS Society
03/29/2018 - 01:37
MS nurses speak out about harm caused by the benefits system
Ekklesia's picture
Ekklesia
03/26/2018 - 22:10
San Diego County Credit Union returns as title sponsor of 2018 Walk MS
San Diego County Credit Union's picture
San Diego Count...
03/23/2018 - 13:34
MS stem cell treatment stabilises disease and reduced disability, trial shows
SheffieldUniv's picture
SheffieldUniv
03/21/2018 - 19:52
Siponimod can slow disability in early secondary progressive MS
MS Society's picture
MS Society
03/20/2018 - 09:06
The Search Continues for More Multiple Sclerosis Treatment Options
Celgene's picture
Celgene
03/18/2018 - 17:21
HSCT works for people with relapsing MS who don't respond to existing DMTs
MS Society's picture
MS Society
03/12/2018 - 11:53
Greensboro Practice Recognized for MS Care
Cone Health's picture
Cone Health
02/27/2018 - 15:55
Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis
Celgene's picture
Celgene
02/16/2018 - 06:25
Regional brain shrinkage in MS predicts disability
UniversityCollegeLondon's picture
UniversityColle...
02/13/2018 - 00:29
Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa (glatiramer acetate injection) 40 mg/mL
Momenta's picture
Momenta
02/05/2018 - 17:31
MS researchers identify new switch for brain repair
MS Society's picture
MS Society
01/12/2018 - 11:23
Ocrelizumab licensed for people with early primary progressive MS in the UK
MS Society's picture
MS Society
01/12/2018 - 01:59
Roches OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Rocheusa's picture
Rocheusa
01/10/2018 - 13:14
Relapse Rates: A Benchmark for Measuring MS Treatment Efficacy
Celgene's picture
Celgene
01/09/2018 - 15:17
Effects of estrogen treatment combat multiple sclerosis in mice
UCLA's picture
UCLA
01/08/2018 - 15:07
Researchers find potential path to repair nerves damaged by multiple sclerosis
UCLA's picture
UCLA
01/04/2018 - 12:44
Lipid metabolism controls regeneration in the central nervous system
Technical University of Munich's picture
Technical Unive...
12/21/2017 - 03:43
NICE proposes restricting future MS treatment options
Ekklesia's picture
Ekklesia
12/20/2017 - 01:30
NICE propose restricting future MS treatment options
MS Society's picture
MS Society
12/14/2017 - 21:28
Boosting resilience to be ready for MS
QueenslandUniv's picture
QueenslandUniv
12/11/2017 - 12:37
Teva Dismisses Litigation After Mylan Wins U.S. Court Ruling Related to Teva's Cold Filtration Patents for Copaxone 40 mg/mL
Mylan's picture
Mylan
11/21/2017 - 14:14
How rogue immune cells cross the blood-brain barrier to cause multiple sclerosis
UICUniv's picture
UICUniv
11/13/2017 - 18:45
Sex differences a rich field for UCLA multiple sclerosis researcher
UCLA's picture
UCLA
11/10/2017 - 08:48
Ocrelizumab: First treatment licensed for some people with primary progressive MS in the UK
MS Society's picture
MS Society
11/10/2017 - 08:08
Roches OCREVUS (ocrelizumab) gains positive CHMP opinion for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Rocheusa's picture
Rocheusa
11/09/2017 - 17:30
Ozanimod Successful in Clinical Trials for Multiple Sclerosis
Scripps Research's picture
Scripps Research
11/03/2017 - 06:29
Cladribine: new oral treatment to be available for people with relapsing MS
MS Society's picture
MS Society
11/02/2017 - 08:39
Blood-Clotting Protein Prevents Repair in the Brain
Gladstone Institutes's picture
Gladstone Institutes
10/31/2017 - 01:57
Gilenya shows promise for treating children with MS
MS Society's picture
MS Society
10/28/2017 - 09:34
Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene's picture
Celgene
10/27/2017 - 10:09
Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Celgene's picture
Celgene
10/27/2017 - 05:58
Treatment Effects Maintained Over Five Years in Patients with Relapsing Remitting Multiple Sclerosis who Received Sanofi Genzymes Lemtrada (alemtuzumab) in Extension Study After Switching from Interferon Beta-1a
Genzyme's picture
Genzyme
10/26/2017 - 10:21
Positive results for clinical trial in progressive MS
MS Society's picture
MS Society
10/26/2017 - 07:51
Mylan Wins UK Court Ruling Related to Copaxone 40 mg/mL Patent
Mylan's picture
Mylan